Pulmonary Embolism

chapter 40 Flashcards | Quizlet   Prevent the formation of clots that inhibit circulation prevent platelet aggregation- uses: Prevent thrombosis in the arteries, Prevention of myocardial infarction or stroke for patients with familial history, Prevention of a stroke for patients having transient ischemic attacks (have TIA, will have stroke) attack and dissolve blood clots that […]

113. A client diagnosed with hypertension begins drug therapy using an antihypertensive agent. The nurse instructs the client’s spouse to remove any objects in the home that can lead to falls. Which client statement confirms that the teaching has been successful? 114. When interpreting the results of a Mantoux test, the nurse explains to the […]

Efficacy and Safety of Low Molecular Weight Heparin Versus Unfractionated Heparin for Prevention of Venous Thromboembolism in Trauma Patients – McMaster Experts   Overview   Research   Identity   Additional Document Info   View All   Overview abstract Purpose Trauma patients are at high risk of VTE. We summarize the efficacy and safety of LMWH […]

Heparin protocol practice 1. Your patient presents to the ED with shortness of breath and is diagnosed with pulmonary embolus. The physician wants you to begin a heparin bolus and drip for anticoagulation. You will need a copy of the heparin protocol to complete these questions. Your patient weighs 180lbs. The time is 0800. A. […]

Abstract Extracted from text … Early lytic treatment of massive pulmonary embolism. Administering the clotdissolving drug alteplase (Actilyse (r) Boehringer Ingelheim) early in the course of massive pulmonary embolism prevents worsening of the disease, a new clinical trial has shown. Patients who benefited from the treatment had signs of rightheart strain at presentation (their hearts […]

anticoags: HEPARIN by Anneke Klomp 1. MOA: accelerates ability of antithrombin to active coag-> 1.1. prevents thrombus prop by facilitating fibrinolysis BUT does not lyse existing thrombi 2. unfractionated 2.1. short half life (rapid anticoag) 2.2. tx of DVT/PE; prophylaxis for VTE; acute coronary syndrome 2.3. safe in pregnancy 2.4. variable dosing -> 2.4.1. adjust […]

Edoxaban (Savaysa) can reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Medication Pearl of the Day: Edoxaban (Savaysa) Indication: Edoxaban (Savaysa) is a factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Insight: Dosing: For NVAF: The […]

7] Heparin 7] A nurse is caring for a hospitalized client who is receiving IV heparin for a deep-vein thrombosis (DVT). The client begins vomiting blood . After the heparin has been stopped, which of the following medications should the nurse prepare to administer? A. Vitamin k1 B. Atropine C. Protamine D. Calcium gluconate [C] […]

A Cross‐Study Analysis Evaluating – Wiley Online Library Study Details: Phase 3 AF Study. The ROCKET AF study (Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) was a prospective, randomized, double-blind, double-dummy, parallel-group, active-controlled, multicenter, event-driven phase 3 study that compared […]

Introduction In this article, you’ll learn about heparin nursing implications and patient teachings. Also, its dosage, indication, side effects. Generic Name: Heparin Sodium Brand Names: Hepalean (CAN), Heparin Leo (CAN), Hep-Lock, Hep-Lock U/P, Heparin Sodium Injection Heparin Class and Category Pharmacologic class: Anticoagulant.   Therapeutic class: anticoagulant, antithromboticAdvertisements Pregnancy category: C Heparin Dosage Adults: subcutaneous: […]

Background: Current evidence suggests that rivaroxaban may be well tolerated and effective in patients with nonvalvular atrial fibrillation (NVAF) and obesity; however, there is limited evidence on the impact of polypharmacy in this population. This study evaluated real-world clinical outcomes with rivaroxaban versus warfarin in patients with NVAF and obesity according to the number of […]

In patients with cancer-associated thrombosis (CAT) who switched to rivaroxaban treatment after at least 4 weeks of standard anticoagulation therapy, the observed incidence proportions of recurrent venous thromboembolism (VTE) and bleeding events were in line with the recognized effectiveness and safety profile of rivaroxaban for the treatment of CAT, according to the results of a […]

Rivaroxaban, a novel oral anticoagulant, plays an important role in the prevention and treatment of thromboembolic diseases. Compared with traditional anticoagulants, rivaroxaban has the characteristics of definite curative effect, good safety, convenient use, and no need to monitor blood coagulation indicators frequently. It is widely used in hip (or knee) joint replacement, deep vein thrombosis, […]

A friend left a message to Hua Zi, asking aspirin and rivaroxaban, both of which are used to prevent blood clots, what is the difference and which is better? Hua Zi replied that aspirin and rivaroxaban have different mechanisms of action, and they can be used in combination, but cannot replace each other . When […]

On 12 December, Daiichi Sankyo announced the results of a pooled analysis showing that edoxaban, a direct oral once-daily Factor Xa inhibitor, significantly reduced the risk of developing venous thromboembolism (VTE) following total knee or hip arthroplasty, when compared to enoxaparin.  Patients receiving edoxaban had a lower incidence of a composite of deep vein thrombosis […]

Generic: Rivaroxaban Brand Name: Xarelto Classification: Anticoagulants, antithrombotic, factor Xa inhibitors Therapeutic use: Prevention, treatment of, and reduction of deep vein thrombosis that may lead to pulmonary embolism following knee or hip replacement surgery. Reduction in risk of stroke Action: Acts as selective factor X inhibitor that blocks the active site of factor Xa, inactivating […]

Daiichi Sankyo announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation or venous thromboembolism enrolled in two phase 3 edoxaban studies. The findings of the two subgroup analyses of 1,943 East Asian patients (Japan, mainland China, Korea and Taiwan) enrolled in the ENGAGE AF-TIMI 48 study and 1,101 […]

Apirax® Generic name: Apixaban Pharmacologic Category: Anticoagulant Dosage Forms: Tablet, Oral (2.5 mg, 5 mg) Description: Apixaban is a selective inhibitor of FXa. Apixaban inhibits free and clot-bound FXa and indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development Indications: Reduction of risk of stroke and […]

Generic Drug Name: Heparin Drug Classification : Therapeutic class – anticoagulant Pharmacologic class – anticoagulant Location of metabolism/excretion: Metabolism – Liver Excretion – Urine/Kidneys Nursing Implications/Assessment: History – thromboprophylaxis, DVT, MI, PE, embolisms associated with atrial fibrillation, venous thrombosis, hyperlipidemia, pregnancy Physical – peripheral pulses/perfusion, blood tests, kidney function tests, platelet count, prevention of injury […]

Rivaroxaban is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the treatment of deep vein thrombosis, and pulmonary embolism. Medication Pearl of the Day: Rivaroxaban (Xarelto) Indication: Rivaroxaban is a factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular […]